Investigating how EHD1 affects inflammation in heart disease
EHD1-mediated Inflammation and Resolution in Atherosclerosis
This study is looking at a protein called EHD1 to see how it affects inflammation in heart disease, with the hope of finding new ways to help people with this condition feel better and heal faster.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11063966 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of EHD1, a protein involved in cellular processes, in the inflammation associated with atherosclerotic cardiovascular disease (CVD). By examining how EHD1 influences macrophage function and inflammation resolution, the study aims to identify new therapeutic targets that could improve treatment outcomes for patients with heart disease. The research utilizes advanced techniques like single-cell RNA sequencing to analyze macrophage populations in atherosclerotic plaques from both humans and mice. This approach may lead to innovative strategies to enhance tissue repair and reduce inflammation in affected individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with atherosclerotic cardiovascular disease who experience ongoing inflammation despite standard lipid-lowering therapies.
Not a fit: Patients without atherosclerotic cardiovascular disease or those whose condition is unrelated to inflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce inflammation and improve heart health for patients with atherosclerosis.
How similar studies have performed: Other research has shown promising results in targeting inflammation in cardiovascular disease, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Cai, Bishuang — Icahn School of Medicine at Mount Sinai
- Study coordinator: Cai, Bishuang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.